{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-24-000115","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.089742+00:00","generated_at":"2026-05-30T08:55:51.111945+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AtriCure Q3 2024: revenue $115.9M (+17.9%), loss $0.17/sh, positive cash flow $16.3M","bullets":["Worldwide revenue $115.9M, up 17.9% YoY; U.S. $95.5M (+16.8%), Intl $20.5M (+23.3%).","Net loss per share $0.17 vs $0.20 YoY; adjusted EBITDA $7.9M, up $3.2M from Q3 2023.","Gross margin 74.9%, down 27 bps YoY due to unfavorable product/geographic mix.","Generated $16.3M cash flow from operations in the quarter.","Launched new products; growth driven by open ablation, appendage management, and pain management."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-24-000115","json":"https://secwatch.observer/filing/0001323885-24-000115.json","markdown":"https://secwatch.observer/filing/0001323885-24-000115.md","text":"https://secwatch.observer/filing/0001323885-24-000115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388524000115/0001323885-24-000115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388524000115/atrc-20241029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:55:51.111945+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}